Clinical Trials
52 trialsPATHWAY
National Cancer Center, Japan
Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
National Cancer Centre, Singapore
WinPro
St Vincent's Hospital
PREDICTAM
Erasmus Medical Center
HOT
European Institute of Oncology
HOBOE
National Cancer Institute, Naples
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Sun Yat-sen University
A Study of TY-302 in Patients With Advanced Solid Tumors
TYK Medicines, Inc
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Nalagenetics Pte Ltd
Therapeutic Dose Monitoring (TDM) of Tamoxifen
Karolinska University Hospital
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Kafrelsheikh University
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
Post Graduate Institute of Medical Education and Research, Chandigarh
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Gruppo Italiano Mammella (GIM)
MEGA
Instituto Nacional de Cancer, Brazil
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
National Taiwan University Hospital
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pembro
Mediclinic Middle East
STEP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Shandong Cancer Hospital and Institute
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Chinese Anti-Cancer Association
OTT 17-01
Ottawa Hospital Research Institute
Tamoxifen in Patients With Oesophageal Cancer
University of Nottingham
Cimicifuga
Irmandade da Santa Casa de Misericordia de Sao Paulo
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Peking Union Medical College Hospital
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Decision Aids for Tamoxifen Treatment in Breast Cancer Patients
National Cancer Center, Korea
TGOG1005
Buddhist Tzu Chi General Hospital
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
National Cancer Institute (NCI)
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
National Cancer Institute (NCI)
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
National Cancer Institute (NCI)
Tamoxifen in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
National Cancer Institute (NCI)
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
National Cancer Institute (NCI)
NEST
Asan Medical Center
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
National Cancer Institute (NCI)
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
National Cancer Institute (NCI)
Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer
National Cancer Institute (NCI)
Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma
National Cancer Institute (NCI)
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Tamoxifen Citrate in Patients With Breast Cancer
Centre Hospitalier Universitaire Vaudois
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
King Faisal Specialist Hospital & Research Center
CONSET
Tata Memorial Hospital
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
ASTRRA
Korean Breast Cancer Study Group
Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer
National Cancer Institute (NCI)